USA flag logo/image

An Official Website of the United States Government

Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80562
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
GM077724
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MOLECULAR DESIGN INTERNATIONAL, INC.
111 South Highland Street MEMPHIS, TN 38111-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative
Agency: HHS
Contract: 1R43GM077724-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Recent studies from our laboratory have shown that topical treatment of diabetic rats with RA improves the healing of subsequently-induced abrasion wounds. Based on this, we have proposed the prophylactic use of RA as a way to improve structure/function in diabetic skin at risk for ulcer formation. A potential drawback to this strategy is skin irritation. If retinoid use in diabetic skin provokes irritation, this could result in non-use (as is does in other groups of retinoid users). Additionally, if the degree of irritation is too great, the irritation could counter-act the beneficial effects of retinoid treatment in the at-risk skin. The overall goal of the proposed studies is to determine if topical pretreatment of skin with MDI 301 will, like RA itself, improve healing of subsequently-induced wounds but do so without provoking irritation. If it can be shown that MDI 301 is as effective as RA without the negative consequence seen with RA use, it will provide a better agent for development as a chronic wound preventative. To achieve our overall goal, we will compare the effects of topical MDI 301 treatment with topical RA on dermal structure/function in streptozotocin diabetic (STZ-D) rats and compare healing of abrasion wounds in control rats, STZ-D rats and STZ-D rats that have been pretreated with topical RA or topical MDI 301.

Principal Investigator:

William P. Purcell
9014540797
purcell@moleculardesign.com

Business Contact:

William Purcell
9015291919
PURCELL@MOLECULARDESIGN.COM
Small Business Information at Submission:

MOLECULAR DESIGN INTERNATIONAL, INC.
MOLECULAR DESIGN INTERNATIONAL 99 South Second Street, Suite A-141 MEMPHIS, TN 38103

EIN/Tax ID: 621019562
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No